Race Oncology: Reports $1.8m in cash outflows

Race Oncology Reports $1.8m in cash outflows

  • Race Oncology (RAC) reports $1.8 million in cash outflows for the quarter, an increase from the $931,000 in outflows recorded in the previous quarter
  • The company spent $890,000 during the period for research and development
  • RAC’s focus is Zantrene, a small molecule anti-cancer drug in which the company announced numerous achievements for over the quarter
  • At the end of the period, the company had $37.1 million in cash and cash equivalents
  • Shares closed 2.81 per cent higher today at $2.93 each
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

Swedish Court Delays Judgment in Klarna’s Antitrust Case Against Google

The court's decision is crucial for Klarna's operations in the competitive market. Highlights: Swedish court delays decision on Klarna's...

Morgan Stanley Launches Bitcoin ETF, Expanding Crypto Offerings

The investment firm broadens its reach into the cryptocurrency market. Highlights: Morgan Stanley launches a Bitcoin ETF to enhance...

HSBC Strengthens Position with Hong Kong Stablecoin Issuer License

The banking giant aims to support digital asset initiatives in the region. Highlights: HSBC receives a stablecoin issuer license...

US Treasury Secretary Warns Banks About Anthropic’s New AI Model

Treasury Secretary highlights risks AI poses to financial stability. Highlights: US Treasury Secretary warns banks about the risks of...